

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JACOBIO PHARMACEUTICALS GROUP CO., LTD.**

**加科思藥業集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1167)**

### **INSIDE INFORMATION**

## **JACOBIO'S KRAS G12C INHIBITOR GLECIRASIB APPROVED FOR MARKET LAUNCH**

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that according to the official website of the National Medical Products Administration (NMPA), the Company has received approval for its independently developed KRAS G12C inhibitor, glecirasib, to be launched on the market. The approved indication is for patients with non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations who have received at least one prior systemic therapy. This approval triggers a milestone payment from the Company’s partner Shanghai Allist Pharmaceuticals Co., Ltd. (上海艾力斯醫藥科技股份有限公司) (688578.SH) (“**Allist**”), of which the Company will receive a milestone payment of RMB50 million.

The approval of glecirasib is based on a pivotal Phase II clinical trial conducted in China, with full data published in *Nature Medicine* (impact factor 58.7). Based on the positive results from the pivotal Phase II single-arm study, in patients with NSCLC treated with glecirasib monotherapy in the second-line or later setting, glecirasib demonstrated an objective response rate (ORR) of 49.6%, a disease control rate (DCR) of 86.3%, a median progression-free survival (PFS) of 8.2 months, and a median overall survival (OS) of 17.5 months in previously treated patients with KRAS G12C-mutated advanced NSCLC. Safety data indicate that glecirasib has a favorable safety profile, particularly with gastrointestinal tolerability among approved KRAS G12C inhibitors. The Company has out-licensed the rights of glecirasib in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan) to Allist.

## **About Glecirasib**

Glecirasib (JAB-21822) is a KRAS G12C inhibitor developed by Jacobio. A number of clinical trials of glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include combination therapy trials with SHP2 inhibitor sitnepatib (JAB-3312) in NSCLC and with cetuximab in colorectal cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China.

## **About Jacobio**

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Jacobio's pipeline revolves around novel molecular targets on six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Jacobio's vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

**Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** There is no assurance that glecirasib (JAB-21822) will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit [www.jacobiopharma.com](http://www.jacobiopharma.com) for more information.

By Order of the Board  
**JACOBIO PHARMACEUTICALS GROUP CO., LTD.**  
**Yinxiang WANG**  
*Chairman*

Hong Kong, May 22, 2025

*As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr. Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.*